

### **REMARKS**

Entry of this amendment after final action is requested under 37 C.F.R. 1.116 to place the claims in better condition for allowance. Upon entry of this amendment, claims 1-6, 9-10 and 17-23 will be currently pending. Claims 7 and 8 are cancelled herein, claims 11-16 were previously withdrawn and claims 17-23 have been newly introduced herein. Amendment and/or cancellation of claims herein is made without abandonment of the original subject matter; Applicants' reserve the right to pursue claims of the original or similar scope in a duly filed continuing application.

Claim 1 has been amended to include limitations of claims 7 and 8. In addition, support for the recitation of "carried by the vector" in amended claim 1 is found on page 4, line 20, and page 7, line 12, of the application as originally filed. Support for the recitation of "capable of inducing an antibody response" is found at page 7, lines 12-13, and support for "capable of inducing a T cell response" is disclosed in the headline in the middle of page 5 of the specification. Support for "the T cell response is biased towards an inflammatory T-helper response" is found on page 7, last paragraph of the specification.

Claims 2-6 and 9-10 have been amended to replace "according to" with "of" as requested by the Examiner. Misspellings such as "listeriolysin" in claim 9 have been corrected.

Support for new claim 17 can be found in the specification as originally filed on page 7, last paragraph. Support for new claim 18 is found at page 7, third and fourth paragraphs. Support for new claim 19 is found at page 4, lines 13 and 18. Support for claim 20 is found at page 4, line 20, and page 8, last line. Support for claim 21 (induction of antibody response after a single immunization) is found on page 7, lines 13-14 and in Figures 3A and 3B. Support for claim 22 (T cell response induced after a single immunization) is found at page 6, first line in the second paragraph for CD8 and page 6, last paragraph, fourth line from the bottom, for CD4, as well as in Figures 1C, 1F, 2C and 2F. Support for claim 23 is found in claim 9.

Thus, all claim amendments herein find basis in the original specification and no new matter has been introduced.

### **OUTSTANDING REJECTIONS**

Various objections to the abstract, specification and claims were maintained for reasons set forth in the Office Action mailed March 29, 2002.

The rejections of claims 1-10 under 35 U.S.C. § 112, second paragraph for asserted indefiniteness were maintained.

The rejections of claims 1-10 under 35 U.S.C. § 112, first paragraph as assertedly lacking enablement for the full scope of the claims were maintained.

The rejections of claims 1-4, 7, 8 and 10 under 35 U.S.C. § 102(e) over Curtiss, III *et al.*, U.S. patent No. 5,656,488 (hereafter "Curtiss, III"), were maintained.

The rejections of claims 1, 2, 7, 8 and 10 under 35 U.S.C. § 102(b) over Srinivasan, *et al.*, *Biol. Reproduct.* 53:462-471 (1995) (hereafter "Srinivasan") were maintained.

The rejections of claims 1-10 under 35 U.S.C. § 103(a) over Curtiss III in view of Rock, U.S. Patent No. 5,869,057 (hereafter "Rock"), Vogelstein *et al.*, U.S. Patent No. 6,054,570 (hereafter "Vogelstein") or Chada *et al.*, U.S. Patent No. 5,736,388 (hereafter "Chada"), were maintained.

### **RESPONSE**

#### **1. Objections to the abstract, specification and claims**

The objection to the abstract was previously addressed by the presentation of a new abstract in Applicants' amendment mailed August 29, 2002. The new abstract is one paragraph and less than 150 words and is believed to comply with MPEP 608.01(b).

The objection to the specification as being informal in format was previously addressed by Applicants' amendment mailed August 29, 2002, which inserted appropriate section headings and a new Summary of the Invention section.

The objection to the specification as incorporating material by reference to a foreign application is addressed herein by Applicants' amendment of the specification to remove the incorporation by reference.

The objection to the specification for use of the abbreviation "CMV" is addressed herein by Applicants' amendment of the specification to insert the corresponding full name "cytomegalovirus". It is well known in the art that CMV is a standard abbreviation for cytomegalovirus and so antecedent basis for this term in the specification is not required. (See, for example, page 171 of Renato Dulbecco, "Virology", 2nd Edition (1988), and the subject index on page 1303 of Fields *et al.*, "Fundamental Virology", 3rd Edition (1996), attached hereto as Exhibits A and B respectively). In fact, the Examiner has used the term "CMV" as an

abbreviation for "cytomegalovirus" as well (see page 14, 4<sup>th</sup> full paragraph, of the August 13, 2003 action).

Although the Examiner objected to the specification for not italicizing names of bacterial species, upon review of the entire specification (including the specific lines on page 5 referred to by the Examiner), Applicants have not identified any bacterial species names that are not italicized.

The objections to the claims have been addressed in Applicants' amendments of the claims. Inasmuch as all of the outstanding objections have been addressed herein or in previous amendments, Applicants believe that these objections may properly be withdrawn.

2. The rejections under 35 U.S.C. § 112, second paragraph

The rejection of claims 1 and 7 for asserted indefiniteness of the term "fragment" may properly be withdrawn in view of Applicants' amendments of the claims to clarify the characteristics of the gene fragment as encoding a polypeptide, a protein and/or a protective antigen that is capable of inducing an antibody and T cell response as recited in amended claim 1.

The rejection of claim 9 for asserted indefiniteness of the term "variant" may properly be withdrawn for the same reason, since claim 9 depends from claim 1 which recites the characteristics of the variant.

The rejection of claim 8 for asserted indefiniteness of the term "protective" is mooted by cancellation of this claim.

For these reasons, Applicants believe that all rejections under 35 U.S.C. § 112, second paragraph may properly be withdrawn as not applicable to the currently pending amended claims.

3. The rejections under 35 U.S.C. § 112, first paragraph

The rejection of all claims 1-10 as assertedly lacking enablement for the full scope of the claim may properly be withdrawn because it would not require undue experimentation to construct gene fragments encoding fragments of polypeptides that elicit the desired immune response recited in claim 1. In fact, the specification shows that the attenuated *Salmonella* vaccine elicited an immune response for at least three completely different polypeptides,  $\beta$ -galactosidase, listeriolysin and ActA.

The Examiner's reliance on the specification's example of the ActA gene fragment encoding amino acids 31-613 as evidence of unpredictability is misplaced. The specification

shows that, in fact, the gene fragment generated both cellular and antibody immune responses, although these responses were not sufficient to rescue mice challenged with lethal doses of *Listeria*. The cellular immune response is demonstrated in Figs. 2D-2F described at page 16, lines 9-14 of the specification and the antibody immune response is demonstrated in Figs. 3A-3B described at page 16, lines 17-23 of the specification). Thus, while the specification reported that actA was non-protective against a lethal bacterial infection, the specification showed that actA did induce an immune response.

It would require no more than routine effort to prepare fragments and test them for desired activity following the guidance of the specification. In view of the guidance provided in the specification, including three working examples, the high level of skill in the art, and the well established knowledge in the art that fragments of proteins can retain antigenic properties of the whole protein, it would not require undue experimentation to produce additional vaccines having the properties recited in claim 1. According to *In re Wands*, 858 F.2d 731, 8 USPQ2d 1400 (Fed. Cir. 1988), even a large quantity of experimentation is not considered "undue" provided it is only routine experimentation.

4. The rejections under 35 U.S.C. § 102(e)

Curtiss, III does not anticipate Applicants' claimed invention because Curtiss, III does not disclose or suggest that the vector carried by the avirulent microbe includes a gene sequence that encodes a polypeptide, a protein and/or a protective antigen which is capable of inducing an antibody response and a T cell response biased towards an inflammatory T cell helper response, as recited in claim 1. On the contrary, Curtiss, III focuses on the antibody (B cell) response and merely discloses that genes encoding gamete-specific antigens are useful for the production of monoclonal and polyclonal antibodies (column 49, lines 43-46). In column 42, line 34 and lines 51-59 the patent only refers to a test for IgG/sIgA responses, which are only B cell responses. Similarly, column 42, line 41-59 merely discloses that a humoral and secretory immune response was tested.

The goal of Curtiss, III is to induce an antibody response, including secretory antibody, to gamete-specific antigens in order to provide an anti-fertility vaccine. Although column 5, lines 60-61 and column 6, lines 26-29 mention a cellular (T cell) response as part of general definitions of the terms "antigen" and "immune response," the Curtiss, III patent makes clear at column 6, lines 34-65 that its disclosure is restricted to the antibody (B cell) response. In particular, lines 45-49 state that "in this application the phrase ["immune response"] is restricted

to the anatomical features and mechanisms by which a multi-cellular organism produces antibodies against an antigenic material . . ."

For these reasons, Curtiss, III does not disclose or suggest all features of claim 1 as amended and, therefore, Curtiss, III does not anticipate claim 1 or claims dependent thereon.

5. The rejections under 35 U.S.C. § 102(e)

Srinivasan does not anticipate Applicants' claimed invention because the reference does not disclose or suggest that the vector carried by the avirulent microbe includes a gene sequence that encodes a polypeptide, a protein and/or a protective antigen which is capable of inducing an antibody response and a T cell response biased towards an inflammatory T cell helper response, as recited in claim 1. This reference, like Curtiss III, also focuses on the secretory antibody response to immunization with gamete-specific antigens. Although Srinivasan mentions a B cell and T cell response in the sentence bridging pages 462-463 and at page 469, left column, it does not disclose or suggest an attenuated *Salmonella* strain comprising a vector that provides a T cell response biased towards an inflammatory T cell helper response.

For these reasons, Srinivasan does not disclose or suggest all features of claim 1 as amended and, therefore, Srinivasan does not anticipate claim 1 or claims dependent thereon.

6. The rejections under 35 U.S.C. § 103

There is not a proper suggestion to combine the references cited by the Examiner, Curtiss, III, Rock, Vogelstein and Chada. Moreover, even if the references are improperly combined, the combination does not successfully teach production of Applicants' claimed invention.

The disclosure of Curtiss, III is discussed above. There is no suggestion and no incentive to combine Curtiss, III with Rock because the two references are focused on solving different problems. Curtiss, III relates to vaccines that produce an antibody response, preferably a secretory antibody response, while Rock teaches using recombinant vaccines to break self-tolerance by fusing a microbial gene product with a self protein. Although Rock generally describes the role of T cells and T-cell help in the immune response and does refer to *Salmonella* as one type of strain that has been used for oral immunization, Rock does not disclose an attenuated *Salmonella* comprising a vector including a gene sequence that encodes a polypeptide, a protein and/or a protective antigen which is capable of inducing an antibody response and a T cell response biased towards an inflammatory T cell helper response, as recited in claim 1.

Vogelstein teaches the selective expression of desired genes in cells expressing oncogenes, and does not mention an attenuated *Salmonella* vaccine for inducing an immune response. Chada merely teaches bacterial phage-mediated gene transfer systems capable of transfecting eukaryotic cells and does not mention an attenuated *Salmonella* vaccine for inducing an immune response. Therefore there is no specific suggestion to combine Curtiss, III with Vogelstein or Chada, and even if combined the references do not lead the skilled person to the invention claimed by independent claim 1.

For these reasons, the references are not properly combined and even if combined do not successfully teach production of an attenuated *Salmonella* vaccine with all the characteristics recited in claim 1. Therefore, the references do not render obvious claim 1 or claims dependent thereon.

**CONCLUSION**

For the foregoing reasons, each of claims 1-6, 9, 10 and 17-23 is believed to be in condition for allowance. Accordingly, the Examiner is respectfully requested to withdraw the outstanding rejections of the claims and to pass this application to issue.

Dated: November 13, 2003

Respectfully submitted,

By Li-Hsien Rin-Laures

Li-Hsien Rin-Laures, M.D.  
Registration No.: 33,547

MARSHALL, GERSTEIN & BORUN  
6300 Sears Tower  
233 S. Wacker Drive  
Chicago, Illinois 60606  
Telephone: (312) 474-6300

Attorneys for Applicant

# FUNDAMENTAL VIROLOGY

*Third Edition*

---



# FUNDAMENTAL VIROLOGY

*Third Edition*

---

---

## *Editors-in-Chief*

→ **Bernard N. Fields, M.D.**

*Department of Microbiology  
and Molecular Genetics  
Harvard Medical School  
Boston, Massachusetts*

**David M. Knipe, Ph.D.**

*Department of Microbiology  
and Molecular Genetics  
Harvard Medical School  
Boston, Massachusetts*

**Peter M. Howley, M.D.**

*Department of Pathology  
Harvard Medical School  
Boston, Massachusetts*

## *Associate Editors*

**Robert M. Chanock, M.D.**

*Laboratory of Infectious Diseases  
National Institute of Allergy and Infectious  
Disease  
National Institutes of Health  
Bethesda, Maryland*

**Joseph L. Melnick, Ph.D., Sc.D.**

*Department of Virology and  
Epidemiology  
Baylor College of Medicine  
Texas Medical Center  
Houston, Texas*

**Thomas P. Monath, M.D.**

*Ora Vax, Inc.  
Cambridge, Massachusetts*

**Bernard Roizman, Sc.D.**

*Department of Molecular Genetics  
and Cell Biology  
University of Chicago  
Chicago, Illinois*

**Stephen E. Straus, M.D.**

*Laboratory of Clinical Investigation  
National Institutes of Health  
Bethesda, Maryland*



**LIPPINCOTT WILLIAMS & WILKINS**

*A Wolters Kluwer Company*

Philadelphia • Baltimore • New York • London  
Buenos Aires • Hong Kong • Sydney • Tokyo

Lippincott Williams & Wilkins, 227 East Washington Square,  
Philadelphia, PA 19106

© 1996 by Lippincott-Raven Publishers. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher.

Made in the United States of America

#### Library of Congress Cataloging-in-Publication Data

Fundamental virology / editors-in-chief, Bernard N. Fields, David M. Knipe, Peter M. Howley ; associate editors, Robert M. Chanock . . . [et al.]—3rd ed.

p. cm.

Consists of selected chapters reprinted from: Fields virology. 3rd ed. 1996  
Includes bibliographical references and index.

ISBN 0-7817-0284-4

I. Virology. I. Fields, Bernard N. II. Knipe, David M. (David Mahan).  
III. Howley, Peter M. IV. Fields virology.

[DNLM: 1. Viruses. 2. Virus Replication. QW 160 F981 1995]

QR360.F847 1995

616'.0194—dc20

DNLM/DLC

for Library of Congress

95-31493

The material contained herein appeared in *Fields Virology*, Third Edition, edited by Fields, Knipe, Howley, et al. Lippincott-Raven Publishers, Philadelphia © 1996.

Great care has been taken to maintain the accuracy of the information contained in the volume. However, neither Lippincott Williams & Wilkins nor the editors can be held responsible for errors or for any consequences arising from the use of the information contained herein.

Materials appearing in this book prepared by individuals as part of their official duties as U.S. Government employees are not covered by the above-mentioned copyright.

9 8 7 6 5 4 3

- enus, 53  
 pathway of activation of, 330  
 effects of, 330-331  
 pathway of activation of, 330  
 nplex virus protein interaction with,  
 rus-infected cells by, 331  
 proteins in regulation of, 1183  
 t receptors, HIV attachment and  
 nalization and, 875  
 t regulatory proteins, poxvirus,  
 itary DNAs, animal viruses in  
 overy of, 8  
 itation, 122-124  
 l activity of recombinant DNA  
 es of viral genomes assessed with,  
 -105  
 quences used in, 124  
 ses, 708  
 r resolution, in poxvirus DNA  
 ication, 1178  
 transition, N to H antigen  
 sformation and, 511  
 infections, adenovirus  
 troenteritis, 979  
 mean hemorrhagic fever virus, 649  
 nt of, coding strategies of, 655  
 : of, 650, 651  
 a, as entry site in viral infection, 167  
 itis, adenoviruses causing, 979  
 s genus (insect parvovirus group C),  
 52, 1018  
 n strain, of vaccinia virus, genome  
 1167-1168  
 ce recombination, mapping  
 tations and, 120  
 id)-envelope link (CEL), HIV, 849  
 otors, HIV, 878-879  
 ins. *See also* Capsid proteins  
 1-853  
 cleavage in production of, 851, 852  
 e and, 182-183  
 s B virus, 1201  
 s, 695, 696  
 uses (Coronaviridae), 31-33, 54,  
 1-559  
 pathogens, 32-33  
 ly of, 552  
 ent of, 546-548  
 eristics of, 24, 31-32  
 cation of, 541-542  
 hic effects of, 552-553  
 ve-interfering RNA and, 554  
 : associations of, 542  
 s of, 553-554  
 e of, structure and organization of,  
 15  
 . of, 545-546  
 coprotein of, 551  
 nge of, 542  
 pathogens, 32. *See also* Human  
 ronavirus  
 n of, 545-546  
 :oprotein of, 551  
 on of, 553  
 :phoprotein of, 551-552  
 nonstructural proteins of, 552  
 penetration by, 546-548  
 persistent infection caused by, 552-553  
 proteins of, processing and intracellular  
 transport of, 551-552  
 receptors for, 175, 546-548  
 replication of, 546-553  
     RNA replication and, 550-551  
     RNA transcription and, 548-550  
 RNA recombinations and, 553-554  
 S glycoprotein of, 551  
 serogroups of, 541, 542  
 transcription in, 548-550  
 translation in  
     of genomic RNA, 548  
     of viral proteins, 551  
 virion of, structure of, 542-545  
 virion release by, 552  
 Corticosteroids, for prion diseases, 1282  
 Corticoviridae, 51  
 Corticovirus genus, 51  
 COS cells, for transient expression, 126  
 Cotransfection, with selectable markers,  
 125-126  
 Cottontail rabbit papillomavirus (CRPV), 952  
     discovery of, 947  
     genomic organization of, 954  
 Cowpea mosaic virus, 390  
     genome organization and expression of, 390,  
     392  
     virion structure of, 390, 391  
 Cowpox virus, 1165  
     cytokine antiviral actions inhibited by, 359  
 Coxsackieviruses  
     electrostatic nature of attachment of, 497  
     type A  
         cell tropism of, 498  
         receptors for, 499  
         families of, 498  
     type B, receptors for, 499  
         families of, 498  
         nature of, 499  
 Cp promoter, BZLF1 interaction with, 1138  
 CPE. *See* Cytopathic effects  
 CPMV. *See* Cowpea mosaic virus  
 CPV. *See* Canine parvovirus  
 CQI. *See* Calchaqui  
 CR1 protein, in herpes simplex virus  
     attachment, 1053  
 CR2 protein (CD21), as virus receptor, 175  
     for Epstein-Barr virus, 1116-1117  
     latent infection in B-lymphocytes and,  
     1118  
 Creutzfeldt-Jakob disease, 1246, 1247  
     familial, 1246, 1247, 1279  
     codon 129 homozygosity and, 1281  
     PrP mutations in, 1280  
     genetic mutations in, 1280  
     iatrogenic, 1247, 1276, 1278  
     codon 129 affecting susceptibility to, 1281  
     incidence of, 1246  
     sporadic, 1246, 1247  
     treatment of, 1282  
 Crimean-Congo hemorrhagic fever virus, 649  
     S segment of, coding strategies of, 655  
     structure of, 650, 651  
 Crk oncogene, 275, 276  
 crmA gene, cytokine antiviral actions inhibited  
     by, 359  
 cRNA (template RNA), influenza virus, 605  
 Cro protein, in cell commitment after  $\lambda$  phage  
     infection, 464-465  
 Crop plants, virus/viroid infection of, 368-369.  
     *See also* Plant viruses  
 Cross-protection, in control of plant virus  
     diseases, 370  
 CRPV. *See* Cottontail rabbit papillomavirus  
 Cryparin, in virus induction of hypovirulence,  
     438  
 Cryphonectria parasitica  
     reovirus of, 438  
     replicons of, 430, 446  
     viruses affecting virulence of, 426-427,  
     437-438  
 Cryptic infections, parvoviruses causing, 1026  
 Cryptoviruses, 377  
 Crystallization of viruses, x-ray diffraction  
     studies and, 62  
 cs mutations. *See* Cold-sensitive mutations  
 CSF. *See* Cerebrospinal fluid; Cytostatic factor  
 CSF-1. *See* Colony-stimulating factor-1  
 CSFs. *See* Colony-stimulating factors  
 c-src. *See* Src oncogene  
 CTL. *See* Cytotoxic T lymphocytes  
 CTV. *See* Citrus tristeza virus  
 Cucumber mosaic virus, 394  
 Cucumovirus genus, 54  
 Cutter incident, 189  
 Cypovirus genus (cytoplasmic polyhedrosis  
     viruses), 38-39, 52, 403  
 Cystoviridae, 52  
 Cystovirus genus, 52  
 Cytokine synthesis inhibitor factor. *See*  
     Interleukin 10  
 Cytokines, 341-365  
     classification of by function, 343  
     in cytotoxic T lymphocyte activity, 327  
     general features of, 341-342  
     in immune response, 328-329  
     induction of synthesis of, 347-349  
         by reoviruses, 720-720  
     interference with in viral persistence, 216  
     receptors for, 349-352  
     reovirus induction of, 720-720  
     signal transduction by, 349-352  
     types of, 342-346  
     viral infection affected by, 185, 356-357  
         therapeutic applications and, 359-360  
     viral replication affected by, 352-356  
     viral strategies for counteraction of actions  
         of, 357-359  
     viruses activating, 349  
 Cytolytic effect, restriction of, persistence and,  
     210-212  
 Cytomegaloviruses (CMV), 45-46, 51  
     cytokines induced by, 349  
     as helper viruses  
         functions of, 1027-1028  
         inhibition of, 1035  
     lymphocytes and monocytes infected by, 333  
     murine (*Muromegalovirus* genus), 45-46, 51  
     persistence of, 208  
     receptors for, 175, 176  
 Cytopathic effects (CPE), 240-241. *See also*  
     Cytopathogenicity  
         of bunyaviruses, 667  
         of coronaviruses, 552-553  
         of picornaviruses, 504-505

# Virology

*Second Edition*

## *Renato Dulbecco, M.D.*

*Distinguished Research Professor,  
The Salk Institute, San Diego;  
Senior Clayton Foundation Investigator and Professor Emeritus,  
Departments of Pathology and Medicine,  
University of California, San Diego, School of Medicine,  
La Jolla, California*

## *Harold S. Ginsberg, M.D.*

*Higgins Professor of Microbiology and Medicine,  
Columbia University College of Physicians and Surgeons,  
New York, New York*



**J. B. LIPPINCOTT COMPANY**  
Philadelphia

London Mexico City New York St. Louis São Paulo Sydney

*Virology, 2nd ed. is also published as a section of Microbiology, 4th ed,  
by Davis, Dulbecco, Eisen, and Ginsberg, published by J. B. Lippincott  
Company.*

Acquisitions Editor: Lisa A. Biello  
Sponsoring Editor: Richard Winters  
Manuscript Editor: Lee Henderson  
Indexer: Betty Herr Hallinger  
Design Coordinator: Caren Erlichman  
Designer: Arlene Putterman  
Cover Designer: Anthony Frizano  
Production Manager: Carol A. Florence  
Production Coordinator: Kathryn Rule  
Compositor: Bi-Comp, Inc.  
Printer/Binder: The Murray Printing Company  
Cover Printer: New England Book Components

Second Edition

Copyright © 1988, by J. B. Lippincott Company

Copyright © 1980, by Harper & Row, Publishers, Inc.

All rights reserved. No part of this book may be used or reproduced in any manner whatsoever without written permission except for brief quotations embodied in critical articles and reviews. Printed in the United States of America. For information write J. B. Lippincott Company, East Washington Square, Philadelphia, Pennsylvania 19105.

6 5 4 3 2

Library of Congress Cataloging-in-Publication Data

Dulbecco, Renato, DATE

Virology.

"Also published as a section of Microbiology, 4th ed.,  
by Davis, Dulbecco, Eisen, and Ginsberg."

Includes bibliographies and index.

1. Medical virology. I. Ginsberg, Harold S.,

DATE. II. Title. (DNLM: 1. Viruses.

QW 160 D879v)

QR360.D84 1988 616'.0194 87-21353

ISBN 0-397-50905-7

Cover photograph from Choppin PW et al: J Exp Med 112:945, 1960,  
courtesy of Rockefeller University Press.

susceptibility in seronegative adults or immunologically crippled children after exposure, as a basis for early prophylaxis with immune globulin.

### EPIDEMIOLOGY AND CONTROL


Varicella virus is usually transmitted in respiratory secretions, producing a highly communicable disease with high clinical attack rate. Epidemics are common among children, especially in the winter and spring. Second attacks of chickenpox apparently do not occur. Herpes zoster, in contrast, is of low incidence, is not seasonal, is recurrent, and is predominantly confined to persons over 20 years of age. As has been pointed out, a case of herpes zoster may initiate an outbreak of chickenpox, and contact with chickenpox is said to provoke attacks of shingles in partially immune persons.

An attenuated viral vaccine has been developed and undergone intensive study in immunocompromised children, particularly those with leukemia receiving chemotherapy, as well in healthy, nonimmune young children. Mild rashes and fever follow immunization in as many as 35% to 40% of children undergoing therapy, and shingles may also subsequently appear. In leukemic children receiving maintenance chemotherapy, treatment is usually suspended from 1 week before to 1 week after immunization. Serum Abs appeared in approximately 90% of these children, the attack rate after exposure was reduced from about 90% to 20%, and all cases were extremely mild.

In view of the seriousness of varicella in adults, however, one might question the wisdom of attempts to prevent infection in healthy children unless the preventive procedure can offer as lasting protection as the natural disease. As in measles (see Measles, Prevention and Control, Chap. 57), chickenpox can be prevented or modified by administering high-Ab-titer IgG to contacts within 72 hours of exposure. Prophylaxis is of particular importance for susceptible adults and for children with impaired immunity. Adenine arabinoside (vidarabine) and acyclovir (see Chap. 49) have been used with apparent success to treat disseminated disease in the seriously ill (particularly in immunologically suppressed patients) as well as in some normal adults, but additional control studies are necessary.


### Cytomegalovirus (Salivary Gland Virus) Group

Salivary gland virus disease of newborns is a severe, often fatal illness, usually affecting the salivary glands, brain, kidneys, liver, and lungs. M. G. Smith, in 1956, isolated the causative agent. The term *cytomegalovirus* (CMV) was applied to the group because of the large size of the infected cells and their huge intranuclear inclusion



**Figure 53-10.** Enveloped full particle of human cytomegalovirus. (Original magnification  $\times 405,000$ ; Wright HT Jr et al: *Virology* 23:419, 1964)

bodies. Assignment to the herpesvirus family was based on the morphology of the viral particle (Fig. 53-10), the chemical composition of the virion (see Characteristics of Members of the Herpesvirus Family), and the characteristics of the intranuclear inclusion body present in infected cells (Figs. 53-11 and 53-12).



**Figure 53-11.** Electron micrograph of a portion of an intranuclear inclusion in a cell infected with human cytomegalovirus. The inclusion is made up of viral particles in various stages of development. Particles are composed of a central core about 40 nm in diameter, surrounded by a pale zone and, externally, by a thin membranous shell. Only a few particles have a dark central core, indicating the presence of nucleic acid. (Original magnification  $\times 40,000$ ; Becker P et al: *Exp Mol Pathol* 4:11, 1965)